# BT-115386, a MAT2A inhibitor, targets MTAP-deficient nasopharyngeal carcinoma via c-Myc and p53 modulation

Source: [cell.com](https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00590-2?rss=yes) · 2026-11-18 · Medicine
Page: https://themorning.science/story/bt-115386-a-mat2a-inhibitor-targets-mtap-deficient-nasopharyngeal-carcinoma-via-b1acf8074645f69e
Kind: research · Impact: medium

## In brief

- MTAP homozygous deletion occurs in 37.5% of Epstein-Barr virus-associated nasopharyngeal carcinomas, according to the source.
- Chan et al. report that the oral MAT2A inhibitor BT-115386 achieved robust tumor suppression in nasopharyngeal carcinoma.
- The authors state that BT-115386 works by targeting PRMT5 to degrade c-Myc and restore p53 signaling.

## Why it matters

The study points to MTAP deficiency as a possible patient-selection marker for MAT2A or PRMT5-pathway drugs in a cancer type where it is common. Readers should note that the source describes the mechanism but does not report clinical outcomes.

## Timeline

- 2026-11-18: Study published in Cell Reports Medicine

## Coverage

- [BT-115386, a MAT2A inhibitor, targets MTAP-deficient nasopharyngeal carcinoma via c-Myc and p53 modulation](https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00590-2?rss=yes) — cell.com, 2026-11-18

Tags: nasopharyngeal carcinoma, mat2a, mtap deficiency, prmt5, cancer therapy

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
